Agilent Form 4: CEO Sells 2,000 Shares Under 10b5-1 Plan

Rhea-AI Filing Summary

Padraig McDonnell, who is listed as President and CEO and a Director of Agilent Technologies (A), reported a sale of 2,000 shares of Agilent common stock on 09/02/2025 at a reported price of $124.88 per share. After the transaction McDonnell beneficially owned 33,448 shares. The filing notes the sale was executed pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 28, 2025. The Form 4 was signed by an attorney-in-fact on behalf of Mr. McDonnell and filed on 09/04/2025.

Positive

• Transaction executed under a Rule 10b5-1 plan, which provides an affirmative defense and suggests the sale was pre-planned
• Clear disclosure of quantity, price, and post-transaction holdings (2,000 shares sold at $124.88; 33,448 shares held thereafter)

Negative

• Filing does not disclose percentage ownership relative to outstanding shares, limiting assessment of materiality
• No information on reason for sale beyond the 10b5-1 plan, so economic motivations are not specified in the document

Insights

Financial Analyst

TL;DR Insider sale of 2,000 shares under a 10b5-1 plan, reducing holdings to 33,448 shares; transaction appears routine.

The sale of 2,000 shares at $124.88 executed under a pre-established Rule 10b5-1 plan indicates a programmed disposition rather than an ad hoc trade. The filing provides clear quantities and price but does not disclose Mr. McDonnell's total economic exposure or percentage of outstanding shares, limiting assessment of materiality. For investors, the key facts are the number of shares sold, the sale price, and the 10b5-1 plan adoption date.

Corporate Governance Expert

TL;DR Director/CEO sale executed under an established 10b5-1 plan; disclosure is standard and complies with Section 16 filing requirements.

The Form 4 identifies the reporting person as both an officer and director and documents a single disposition reported under code S(1) with an explicit 10b5-1 plan adoption date of March 28, 2025. The signature by an attorney-in-fact and the statement of the plan satisfy customary procedural elements. The disclosure lacks any amendments or additional derivative activity, consistent with a routine executive share sale.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MCDONNELL PADRAIG

(Last) (First) (Middle)

5301 STEVENS CREEK BLVD.

(Street)

SANTA CLARA CA 95051

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
AGILENT TECHNOLOGIES, INC. [ A ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
09/02/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/02/2025		S(1)		2,000	D	$124.88	33,448	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on March 28, 2025.

	/s/ P. Diana Chiu, attorney-in-fact for Mr. McDonnell	09/04/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Agilent (A) insider Padraig McDonnell report on Form 4?

The Form 4 reports a sale of 2,000 shares of Agilent common stock on 09/02/2025 at $124.88 per share, leaving 33,448 shares beneficially owned.

Was the insider sale by Padraig McDonnell part of a 10b5-1 trading plan?

Yes. The filing states the transaction was effected pursuant to a Rule 10b5-1 plan adopted on March 28, 2025.

Who filed the Form 4 for Padraig McDonnell and when was it signed?

The Form 4 was signed by P. Diana Chiu, attorney-in-fact for Mr. McDonnell and dated 09/04/2025.

What price did Padraig McDonnell receive for the sold shares?

The reported sale price was $124.88 per share for the 2,000 shares sold on 09/02/2025.

Does the Form 4 report any derivative transactions for Mr. McDonnell?

No. Table II in the filing contains no reported derivative transactions; only a non-derivative sale is disclosed.